Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China’s National Medical Products Administration (NMPA) for its innovative antiplatelet drug, benzenesulfonate CG-0255. This development marks a significant step forward for the company and its efforts to bring a new treatment option to patients with acute coronary syndrome (ACS).
Category 1 Drug CG-0255: A P2Y12 Receptor Antagonist
The Category 1 drug CG-0255 is a P2Y12 receptor antagonist designed for patients with ACS undergoing percutaneous coronary intervention (PCI), such as angioplasty. The drug’s injectable formulation presents several advantages over current oral antiplatelet therapies, including a faster onset of action, enhanced efficacy, and increased bioavailability. These benefits could potentially lead to improved patient outcomes in the critical care settings where rapid and effective treatment is paramount.
Overcoming Challenges in Existing Antiplatelet Therapies
One of the distinctive features of CG-0255 is its metabolic pathway, which addresses key challenges in current antiplatelet drug therapies. The drug bypasses the cytochrome P450 (CYP) 2C19 enzyme system, which can vary genetically among individuals and impact the effectiveness of conventional antiplatelet medications. By overcoming this variability, CG-0255 has the potential to provide a more reliable and consistent therapeutic option for patients undergoing PCI.-Fineline Info & Tech
